Evidence map›Paper›PMID 8405741›Full record

Trial reportDiabetologia1993

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

M A Nauck, N Kleine, C Orskov, J J Holst, B Willms, W Creutzfeldt

Registry-linked trialOpen access · bronzeAbstract readClinical TrialControlled Clinical Trial
PubMed Publisher
In one paragraph

Trial report in Diabetologia, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00716170 (The Role of GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia), which is not on this map. Cited by 311 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
311citing papers in PubMed, 1 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00716170 completedstarted 2008, after this paper: background citation

The Role of GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia

Ran2008Enrolled10Registered outcomes1Posted comparisons0ConditionsType 2 Diabetes MellitusArmsGlucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)
PMID 17225124PMID 11095432PMID 12189441PMID 8423228PMID 12502614PMID 12664078PMID 12764578PMID 15655703PMID 16401467PMID 7015135PMID 7015132PMID 3905480other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

311 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,087 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Exposure-response analyses of liraglutide 3.0 mg for weight management.Diabetes, obesity & metabolism · 2016 · on this map
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

251 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

M A NauckDepartment of Medicine, Georg-August-University, Göttingen, Germany.
N Kleine
C Orskov
J J Holst
B Willms
W Creutzfeldt
Diabeteszentrum Bad Lauterberg · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucagon-like peptide 1 (GLP-1) (7-36 amide) is a physiological incretin hormone that is released after nutrient intake from the lower gut and stimulates insulin secretion at elevated plasma glucose concentrations. Previous work has shown that even in Type 2 (non-insulin-dependent) diabetic patients GLP-1 (7-36 amide) retains much of its insulinotropic action. However, it is not known whether the magnitude of this response is sufficient to normalize plasma glucose in Type 2 diabetic patients with poor metabolic control. Therefore, in 10 Type 2 diabetic patients with unsatisfactory metabolic control (HbA1c 11.6 +/- 1.7%) on diet and sulphonylurea therapy (in some patients supplemented by metformin or acarbose), 1.2 pmol x kg-1 x min-1 GLP-1 (7-36 amide) or placebo was infused intravenously in the fasting state (plasma glucose 13.1 +/- 0.6 mmol/l). In all patients, insulin (by 17.4 +/- 4.7 nmol x 1-1 x min; p = 0.0157) and C-peptide (by 228.0 +/- 39.1 nmol x 1-1 x min; p = 0.0019) increased significantly over basal levels, glucagon was reduced (by -1418 +/- 308 pmol x 1-1 x min) and plasma glucose reached normal fasting concentrations (4.9 +/- 0.3 mmol/l) within 4 h of GLP-1 (7-36 amide) administration, but not with placebo. When normal fasting plasma glucose concentrations were reached insulin returned towards basal levels and plasma glucose concentrations remained stable despite the ongoing infusion of GLP-1 (7-36 amide). Therefore, exogenous GLP-1 (7-36 amide) is an effective means of normalizing fasting plasma glucose concentrations in poorly-controlled Type 2 diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Indexed as

AdultBlood GlucoseDiabetes Mellitus, Type 2FastingFemaleGlucagonGlucagon-Like Peptide 1Glucagon-Like PeptidesGlycated HemoglobinHumansHyperglycemiaHypoglycemic AgentsInfusions, IntravenousKineticsMaleMiddle AgedBlood GlucoseGlucagonGlucagon-Like Peptide 1glucagon-like peptide 1 (7-36)amideGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsPeptide Fragments

Identifiers

PMID8405741
OpenAlexW2087707716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.